Vaxil Bio Ltd. Completes Non-Brokered Private Placement
Vaxil Bio Ltd. is pleased to announce the successful completion of its previously announced non-brokered private placement, securing a total of $140,000 in gross proceeds. Investors participated by subscribing to 1,244,441 units at a pricing of $0.1125 each. Each unit is made up of one common share and a warrant, with these warrants allowing investors the opportunity to purchase additional shares at an exercise price of $0.15 per share until December 2, 2030.
Details of the Placement and Compensation
As stipulated by Canadian securities regulations, the securities issued as part of the private placement will have a holding period of four months and one day, thus expiring on April 3, 2026. Additionally, Vaxil rewarded its finders with fees totaling $11,200 and 99,555 warrants that carry the same terms as the originally issued warrants. This financial backing is anticipated to bolster Vaxil's initiatives beyond the healthcare sector, aiming to maximize shareholder value.
Changes on the Board of Directors
In a significant operational update, Mr. Ari Kellen and Mr. Shawn Langer have stepped down from their positions on the Board of Directors, effective immediately. Concurrently, Mr. Simon Igelman has been appointed to the board. Igelman, a prominent corporate transactional lawyer, brings a wealth of experience in corporate finance, mergers, and acquisitions, further enhancing the strategic capabilities of Vaxil.
Strategic Insights from Company Leadership
Gadi Levin, Chairman of the Board, acknowledged the critical contributions of Kellen and Langer during their tenures, expressing gratitude for their service. He also extended a warm welcome to Mr. Igelman, expressing optimism about future collaborations as the company explores new strategic pathways, creating value for its shareholders.
Overview of Vaxil's Mission and Vision
Vaxil was built on a foundation of innovation, particularly in the rapidly evolving fields of immunotherapy and biotechnology. The company has historically dedicated itself to addressing significant cancer markers and infectious diseases through its lead product, ImMucin™, which has gained orphan drug designations from both the FDA and EMA. Currently, Vaxil is evaluating diversified business endeavors that may extend beyond the biotech landscape, all aimed at enhancing the value for its shareholders.
Future Direction and Commitment to Shareholders
As Vaxil continues its journey, the focus remains on exploring a wide range of strategic opportunities that promise to foster growth and innovation. The leadership team's commitment to adapting and expanding the company's scope will undoubtedly resonate with their shareholders, allowing them to remain at the forefront of advancements in healthcare and beyond.
Frequently Asked Questions
What recent financial actions did Vaxil Bio Ltd. take?
Recently, Vaxil completed a non-brokered private placement, raising $140,000 for growth opportunities.
Who has joined Vaxil's Board of Directors?
Mr. Simon Igelman has been appointed to the Board, bringing expertise in corporate transactions.
What are the key components of the private placement?
The placement included 1,244,441 units at $0.1125 per unit, consisting of common shares and warrants with a potential exercise price of $0.15.
How will the funds from the private placement be utilized?
The proceeds are expected to assist in exploring strategic options beyond healthcare to maximize shareholder value.
What was the background of Vaxil Bio Ltd.'s lead product?
Vaxil's lead product, ImMucin™, is focused on treating significant cancer markers and has received orphan drug status.
